Market Research Logo

Global Next Generation Cancer Diagnostics Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Next Generation Cancer Diagnostics Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

The global next generation cancer diagnostics market is projected to grow CAGR 32.3% during 2016-2022. The market is anticipated to reach $20.9billion by 2022. The research report is segmented in terms of technology, type, application, and function. The technology segment is further sub segmented as lab on a chip, benchtop sequencer, DNA microarrays, , multiplexed assays, next generation sequencing cellular capture & identification, , RT-PCR & multiplexing, protein microarrays and other technologies. . RT-PCR & Multiplexing is leading the technology segment with market share of 15% in 2015. RT-PCR & Multiplexing has wide range of applications towards cancer research & development. North America has the leading market share of 48% in 2015. Increasing prevalence of cancer, increasing funding for research & development, favourable support from government and regulatory bodies are the driving factors of next generation cancer diagnostics market in North America and Europe. Asia Pacific is the fastest growing next generation cancer diagnostics market for the forecasted period. Asia Pacific market is growing at CAGR 12%.

According to National Institute of Health’s report; An Aging World: 2015, the world’s geriatric population (aged 65 and over) to be 8.5% in 2015. According to the report around 17% of the total world population by 2050 will be aged 65 years and above. Age is the major factor for developing cancer. Around 60% of population aged 65 years and above have cancer. Along with cancer, an individual also suffers from heart conditions, lung disease, and kidney disease. Liver cancer, Kidney cancer, and Stomach cancer are some of the common cancers occurring in geriatric population. Countries like Japan, Germany, Greece, and Italy, with an average geriatric population of over 25% will be a lucrative market for next generation cancer diagnostics. Stringent regulatory guidelines, rising competition among market players, dearth of experienced and skills personnel, high investment capital and varying regulatory compliance rules of different countries are the challenges deliberated in the market research report.

Asia Pacific is the fastest growing next generation cancer diagnostics market for the forecasted period. Asia Pacific market is growing at CAGR 12%. Increasing prevalence of cancer, increasing healthcare expenditure and changing healthcare reforms are the factors driving next generation cancer diagnostic market in Asia Pacific for the forecasted period. BMC Journal in its Cancer Epidemiology estimates over 10.6million new cases of cancer in Asia Pacific by 2030. . Countries like India, Japan, Indonesia and China will drive next generation cancer diagnostic market in Asia Pacific for the forecasted period.

The report segmented next generation cancer diagnostic market on the basis of technology, type, application, and function. The USP of our report is the country level analysis of each geographical region. The research report gives revenue of top five companies in the market, demand of food colorant from end user industries and price of food colorant. The data is gathered via primary and secondary research. The report provides detailed analysis of key market players and their strategies

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. MARKET SCOPE
2. MARKET OVERVIEW
2.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: EVOLUTION & TRANSITION
2.2. INDUSTRY STRUCTURE
2.3. MANUFACTURING PROCESS
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. PRICING ANALYSIS
2.7.6. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.7.7. ROI ANALYSIS
2.7.8. GAP ANALYSIS
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES AND ANALYSIS
2.8.2. MARKET SHARE
2.8.3. TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS & MARKET IMPACT
3.1.1. RISING AGING POPULATION
3.1.2. INCREASING NUMBER OF PRIVATE DIAGNOSTICS CENTERS
3.1.3. FAVORABLE GOVERNMENT SUPPORT
3.1.4. INCREASING PREVALENCE RATE OF CANCER
3.1.5. INCREASING HEALTHCARE EXPENDITURE
3.2. MARKET RESTRAINTS & MARKET IMPACT
3.2.1. HIGH INVESTMENT CAPITAL
3.2.2. DEARTH OF EXPERIENCED AND SKILLED PERSONNEL
3.2.3. VARYING REGULATORY COMPLIANCE RULES OF DIFFERENT COUNTRIES
3.3. MARKET OPPORTUNITIES
3.3.1. RISING TECHNOLOGICAL ADVANCEMENTS
3.3.2. INCREASING HEALTHCARE INDUSTRY
3.3.3. MINIATURIZED ADVANCED DEVICES
3.4. MARKET CHALLENGES
3.4.1. STRINGENT REGULATORY GUIDELINES
3.4.2. RISING COMPETITION AMONG MARKET PLAYERS
4. MARKET SEGMENTATION
4.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY TECHNOLOGY 2014-2022
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. LAB ON A CHIP 2014-2022 ($ MILLION)
4.1.5.1.1. APPLICATIONS
4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.1.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.1.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.1.3.3. PRICE ANALYSIS
4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.5. KEY CONCLUSIONS
4.1.5.2. DNA MICROARRAYS 2014-2022 ($ MILLION)
4.1.5.2.1. APPLICATIONS
4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.2.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.2.3.3. PRICE ANALYSIS
4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.5. KEY CONCLUSIONS
4.1.5.3. MULTIPLEXED ASSAYS 2014-2022 ($ MILLION)
4.1.5.3.1. APPLICATIONS
4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.3.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.3.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.3.3.3. PRICE ANALYSIS
4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.5. KEY CONCLUSIONS
4.1.5.4. RT-PCR & MULTIPLEXING 2014-2022 ($ MILLION)
4.1.5.4.1. APPLICATIONS
4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.4.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.4.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.4.3.3. PRICE ANALYSIS
4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.4.5. KEY CONCLUSIONS
4.1.5.5. PROTEIN MICROARRAYS 2014-2022 ($ MILLION)
4.1.5.5.1. APPLICATIONS
4.1.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.5.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.5.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.5.3.3. PRICE ANALYSIS
4.1.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.5.5. KEY CONCLUSIONS
4.1.5.6. CELLULAR CAPTURE AND IDENTIFICATION 2014-2022 ($ MILLION)
4.1.5.6.1. APPLICATIONS
4.1.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.6.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.6.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.6.3.3. PRICE ANALYSIS
4.1.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.6.5. KEY CONCLUSIONS
4.1.5.7. NEXT GENERATION SEQUENCING 2014-2022 ($ MILLION)
4.1.5.7.1. APPLICATIONS
4.1.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.7.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.7.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.7.3.3. PRICE ANALYSIS
4.1.5.7.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.7.5. KEY CONCLUSIONS
4.1.5.8. BENCHTOP SEQUENCERS 2014-2022 ($ MILLION)
4.1.5.8.1. APPLICATIONS
4.1.5.8.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.8.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.8.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.8.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.8.3.3. PRICE ANALYSIS
4.1.5.8.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.8.5. KEY CONCLUSIONS
4.1.5.9. OTHER TECHNOLOGIES 2014-2022 ($ MILLION)
4.1.5.9.1. APPLICATIONS
4.1.5.9.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.9.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.9.3.1. UNIT SHIPMENTS (MT) 2014-2022 ($ MILLION)
4.1.5.9.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
4.1.5.9.3.3. PRICE ANALYSIS
4.1.5.9.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.9.5. KEY CONCLUSIONS
4.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER TYPE 2014-2022
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. SEX RELATED TUMORS 2014-2022 ($ MILLION)
4.2.5.1.1. APPLICATIONS
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSION
4.2.5.1.6. SEX RELATED TUMOR SUB SEGMENT
4.2.5.1.6.1. CERVICAL CANCER
4.2.5.1.6.2. BREAST CANCER
4.2.5.1.6.3. OVARIAN CANCER
4.2.5.1.6.4. PROSTATE CANCER
4.2.5.2. BLOOD BORN CANCER 2014-2022 ($ MILLION)
4.2.5.2.1. APPLICATIONS
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSION
4.2.5.2.6. BLOOD BORN CANCER SUB SEGMENT
4.2.5.2.6.1. MYELOMA
4.2.5.2.6.2. LEUKEMIA
4.2.5.2.6.3. LYMPHOMA
4.2.5.3. LUNG CANCER 2014-2022 ($ MILLION)
4.2.5.3.1. APPLICATIONS
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5. KEY CONCLUSION
4.2.5.3.5.1. SOLID TUMORS
4.2.5.3.5.2. COLORECTAL CANCER
4.2.5.3.5.3. OTHER CANCER
4.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY FUNCTION 2014-2022 ($ MILLION)
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. PROGNOSIS DIAGNOSTICS 2014-2022 ($ MILLION)
4.3.5.1.1. APPLICATIONS
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. COMPANION DIAGNOSTICS 2014-2022 ($ MILLION)
4.3.5.2.1. APPLICATIONS
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. CANCER SCREENING 2014-2022 ($ MILLION)
4.3.5.3.1. APPLICATIONS
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.3.5. KEY CONCLUSIONS
4.3.5.4. RISK ANALYSIS 2014-2022 ($ MILLION)
4.3.5.4.1. APPLICATIONS
4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.4.5. KEY CONCLUSIONS
4.3.5.5. THERAPEUTIC MONITORING
4.3.5.5.1. APPLICATIONS
4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.5.5. KEY CONCLUSIONS
4.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY APPLICATION 2014-2022 ($ MILLION)
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION
4.4.5.1. PROTEOMIC ANALYSIS 2014-2022 ($ MILLION)
4.4.5.1.1. APPLICATIONS
4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.4.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.1.5. KEY CONCLUSIONS
4.4.5.2. EPIGENETIC ANALYSIS 2014-2022 ($ MILLION)
4.4.5.2.1. APPLICATIONS
4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.4.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.2.5. KEY CONCLUSIONS
4.4.5.3. GENETIC ANALYSIS 2014-2022 ($ MILLION)
4.4.5.3.1. APPLICATIONS
4.4.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.4.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.3.5. KEY CONCLUSIONS
4.4.5.4. BIOMARKER DEVELOPMENT 2014-2022 ($ MILLION)
4.4.5.4.1. APPLICATIONS
4.4.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.4.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.4.5. KEY CONCLUSIONS
4.4.5.5. CTC ANALYSIS 2014-2022 ($ MILLION)
4.4.5.5.1. APPLICATIONS
4.4.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.4.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.5.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF M&A
5.1.2. LIST OF JV
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIP
5.2. TOP 10 COMPANY ANALYSIS – DASHBOARD
6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKETBY REGION (REVENUE ANALYSIS) 2014-2022 ($ MILLION)
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GEOGRAPHIC SEGMENTATION
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY APPLICATION ANALYSIS
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.1.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.1.2.1.3. PRICE ANALYSIS
6.4.1.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.5. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.1.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.1.2.2.3. PRICE ANALYSIS
6.4.1.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.5. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY APPLICATION ANALYSIS
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.1.3. PRICE ANALYSIS
6.4.2.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.5. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.2.3. PRICE ANALYSIS
6.4.2.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.5. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.3.3. PRICE ANALYSIS
6.4.2.2.3.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.5. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.4.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.4.3. PRICE ANALYSIS
6.4.2.2.4.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.5. KEY CONCLUSIONS
6.4.2.2.5. ITALY
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.5.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.5.3. PRICE ANALYSIS
6.4.2.2.5.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.5. KEY CONCLUSIONS
6.4.2.2.6. REST OF EUROPE
6.4.2.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.6.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.6.3. PRICE ANALYSIS
6.4.2.2.6.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.6.5. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY APPLICATION ANALYSIS
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.1.3. PRICE ANALYSIS
6.4.3.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.5. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.2.3. PRICE ANALYSIS
6.4.3.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.5. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.3.3. PRICE ANALYSIS
6.4.3.2.3.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.5. KEY CONCLUSIONS
6.4.3.2.4. SOUTH KOREA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.4.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.4.3. PRICE ANALYSIS
6.4.3.2.4.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.5. KEY CONCLUSIONS
6.4.3.2.5. AUSTRALIA
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.5.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.5.3. PRICE ANALYSIS
6.4.3.2.5.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.5. KEY CONCLUSIONS
6.4.3.2.6. REST OF ASIA PACIFIC
6.4.3.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.6.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.6.3. PRICE ANALYSIS
6.4.3.2.6.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.6.5. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY APPLICATION ANALYSIS
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.4.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.4.2.1.3. PRICE ANALYSIS
6.4.4.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.5. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.4.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.4.2.2.3. PRICE ANALYSIS
6.4.4.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.5. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.2. AGILENT TECHNOLOGIES
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.3. GE HEALTHCARE
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.4. GENOMIC HEALTH INC
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.5. HOLOGIC INC
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.6. ILLUMINA INC
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.7. JOHNSON & JOHNSON
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.8. MYRIAD GENETICS INC
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.9. NOVARTIS AG
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.10. OPKO HEALTH INC
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.11. PERKING ELMER INC
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.12. PHILIPS ELECTRONICS NV
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.13. QIAGEN
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.14. ROCHE HOLDING
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.15. THERMO FISHER SCIENTIFIC INC
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
LIST OF TABLES
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY 2014-2022 ($ MILLION)
GLOBAL LAB ON CHIP MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL DNA MICROARRAYS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL MULTIPLEXED ASSAY MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL RT PCR & MULTIPLEXING MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL PROTEIN MICROARRAYS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL CELLULAR CAPTURE AND IDENTIFICATION MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL BENCHTOP SEQUENCERS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL OTHER TECHNOLOGIES MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY CANCER TYPE 2014-2022 ($ MILLION)
GLOBAL SEX RELATED TUMORS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL CERVICAL CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL BREAST CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL OVARIAN CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL PROSTATE CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL BLOOD BORN CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL MYELOMA CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL LEUKEMIA CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL LYMPHOMA CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL LUNG CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL SOLID TUMORS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL COLORECTAL CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL OTHER CANCER MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY FUNCTION 2014-2022 ($ MILLION)
GLOBAL PROGNOSIS DIAGNOSTICS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL CANCER SCREENING MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL RISK ANALYSIS MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL THERAPEUTIC MONITORING MARKET BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY APPLICATION 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET IN PROTEOMIC ANALYSIS BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET IN EPIGENETIC ANALYSIS BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET IN GENETIC ANALYSIS BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET IN BIOMARKER DEVELOPMENT BY GEOGRAPHY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET IN CTC ANALYSIS BY GEOGRAPHY 2014-2022 ($ MILLION)
NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
REST OF THE WORLD NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
LIST OF FIGURES
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY LAB ON CHIP 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY DNA MICROARRAYS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY MULTIPLEXED ASSAY 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY RT PCR & MULTIPLEXING 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY PROTEIN MICROARRAYS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY CELLULAR CAPTURE AND IDENTIFICATION 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY NEXT GENERATION SEQUENCING 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY BENCHTOP SEQUENCERS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY OTHER TECHNOLOGIES 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY SEX RELATED TUMORS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY CERVICAL CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY BREAST CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY OVARIAN CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY PROSTATE CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY BLOOD BORN CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY MYELOMA CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY LEUKEMIA CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY LYMPHOMA CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY LUNG CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY SOLID TUMORS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY COLORECTAL CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY OTHER CANCER 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY PROGNOSIS DIAGNOSTICS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY COMPANION DIAGNOSTICS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY PROGNOSIS DIAGNOSTICS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY CANCER SCREENING 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY RISK ANALYSIS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY THERAPEUTIC MONITORING 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY PROTEOMIC ANALYSIS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY EPIGENETIC ANALYSIS 2014-2022 ($MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY GENETIC ANALYSIS 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY BIOMARKER DEVELOPMENT 2014-2022 ($ MILLION)
GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY CTC ANALYSIS 2014-2022 ($ MILLION)
UNITED STATES (U.S.) NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
CANADA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
UNITED KINGDOM (UK) NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
FRANCE NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
GERMANY NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
SPAIN NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
ITALY NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
ROE NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
INDIA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
CHINA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
JAPAN NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
KOREA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
AUSTRALIA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
ROAPAC NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
MENA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)
AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET 2014-2022 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report